Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States
Teclistamab was associated with significantly lower treatment costs and numerically lower cost per responder than elranatamab in triple class-exposed RRMM.
Authors
- Bingcao Wu (ORCID: https://orcid.org/0000-0002-7027-8062)
- Elissa E. Min (ORCID: https://orcid.org/0000-0003-2284-2033)
- Jessica Fowler
- Agne Paner
- Suzy Van Sanden
- Nina Kim (ORCID: https://orcid.org/0000-0002-1809-0417)
- Lucio Gordan (ORCID: https://orcid.org/0000-0002-3956-1396)
- Louis P. Garrison (ORCID: https://orcid.org/0000-0002-9468-4989)
- Dee Lin (ORCID: https://orcid.org/0000-0003-2565-7984)
- Eric M. Ammann (ORCID: https://orcid.org/0000-0001-5882-5388)
- Arielle G. Bensimon (ORCID: https://orcid.org/0000-0003-1967-2045)
- Mu Fan (ORCID: https://orcid.org/0000-0001-8095-7424)
- Xinke Zhang (ORCID: https://orcid.org/0009-0008-9564-9369)
- Hoa H. Le (ORCID: https://orcid.org/0000-0001-6755-1331)
- J. Goble
- A. Marshall
Institutions
- Johnson & Johnson (United States) (US)
- University of Washington (US)
- Purdue University West Lafayette (US)
- Florida Cancer Specialists & Research Institute (US)
- Johnson & Johnson (Israel) (IL)
- Johnson & Johnson (Brazil) (BR)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1080/13696998.2025.2514909
- Citations
- 4
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 7.08